Baseline characteristics
| Parameter . | RTX+DXM (n = 62) . | DXM (n = 71) . | P value for difference between groups . |
|---|---|---|---|
| Age, median (IQR) | 51 y (36-63) | 58 y (41-70) | .2 |
| Females, n (%) | 36 (58%) | 34 (48%) | .3 |
| Baseline platelet count ×109/L, median (IQR) | 13 (6-20) | 14 (8-23) | .4 |
| Follow-up period in days, median (IQR) | 921 (526-1152) | 922 (190-1126) | .3 |
| Dexamethasone cycles during treatment | |||
| 1 cycle, no. of patients (%) | 43 (69%) | 40 (56%) | .09 |
| 2-3 cycles, no. of patients (%) | 16 (26%) | 22 (31%) | |
| >4 cycles, no. of patients (%) | 3 (5%) | 9 (13%) | |
| Parameter . | RTX+DXM (n = 62) . | DXM (n = 71) . | P value for difference between groups . |
|---|---|---|---|
| Age, median (IQR) | 51 y (36-63) | 58 y (41-70) | .2 |
| Females, n (%) | 36 (58%) | 34 (48%) | .3 |
| Baseline platelet count ×109/L, median (IQR) | 13 (6-20) | 14 (8-23) | .4 |
| Follow-up period in days, median (IQR) | 921 (526-1152) | 922 (190-1126) | .3 |
| Dexamethasone cycles during treatment | |||
| 1 cycle, no. of patients (%) | 43 (69%) | 40 (56%) | .09 |
| 2-3 cycles, no. of patients (%) | 16 (26%) | 22 (31%) | |
| >4 cycles, no. of patients (%) | 3 (5%) | 9 (13%) | |
IQR, interquartile range.